Hepatitis C virus (HCV) is the major cause of liver disease worldwide and a potential source of high morbidity and mortality in the future. The World Health Organization estimates that ...

Nucleotide analog therapy is complicated by the potential ... Telbivudine has high rate of resistance unless serum hepatitis B virus (HBV) DNA levels are undetectable at 24 weeks.

A study to determine the extent of such blood-borne infections in Ireland also found that the prevalence of both viruses was ...

Despite the standard immunoprophylaxis, a significant portion of infants born to highly viremic mothers remain infected with hepatitis B virus (HBV). Emerging data suggest that antiviral therapy ...

By Dr. Liji Thomas, MD New recommendations address advances in immunosuppressive therapies and highlight antiviral ...

Discover a clinical trial that was conducted to evaluate the efficacy and safety of autologous HBV vaccine-pulsed dendritic cells and their induced T cells.

The American Gastroenterology Association (AGA) updated its clinical practice guidelines for managing hepatitis B ...

Objective: To estimate the cost utility of treatment with combination therapy (ribavirin and interferon α) for hepatitis C compared with no treatment or monotherapy (interferon α) based on UK costs ...

The American Gastroenterological Association (AGA) has unveiled an updated clinical practice guideline in Gastroenterology addressing the prevention and management of hepatitis B virus reactivation ...

The US FDA has granted breakthrough therapy designation to Bluejay Therapeutics’ brelovitug, to treat chronic hepatitis delta ...

The drug has been granted Breakthrough Therapy designation by the FDA for the treatment of chronic hepatitis delta (CHD).

Privately-held US biopharma Bluejay Therapeutics has announced that its lead product candidate brelovitug—also known as BJT-778—has received US Food and Drug Administration Breakthrough Therapy ...